<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01361022</url>
  </required_header>
  <id_info>
    <org_study_id>263.511</org_study_id>
    <nct_id>NCT01361022</nct_id>
  </id_info>
  <brief_title>To Assess the Bioequivalence of Brotizolam Tablets 250 Mcg vs. Lendormin Tablets 250 Mcg Administered to Healthy Adult Volunteers</brief_title>
  <official_title>A Randomized, Single-dose, Two-way Cross-over Study to Assess the Bioequivalence of Lendormin Tablets 0.25 mg (Delpharm Reims) vs. Lendormin Tablets 0.25 mg (Synmosa Biopharma Co. Ltd.) Administered to Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the study was to assess the bioequivalence of Lendormin Tablets (Delpharm
      Reims) vs. Lendormin Tablets (Synmosa Biopharma Co. Ltd.) following oral administration
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax: Peak drug concentration obtained directly from the data without interpolation</measure>
    <time_frame>One month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>kel:Plasma elimination rate constant determined by simple linear regression based on the terminal phase of plasma concentration</measure>
    <time_frame>One month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax:Time to peak drug concentration obtained directly from the data without interpolation</measure>
    <time_frame>One month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T 1/2: Plasma half-life estimated by (0.693/kel)</measure>
    <time_frame>One month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MRT : Mean residence time</measure>
    <time_frame>One month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUMC : Area under the ( first) moment plasma concentration - time curve</measure>
    <time_frame>One month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0-t: Area under the plasma concentration-time curve from zero to the last quantifiable concentration determined by the traperoidal rule</measure>
    <time_frame>One month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0- : Area under the plasma concentration-time curve from time zero to infinity determined by the trapezoidal rule and extrapolated to infinity estimated by the last quantifiable concentration (Cn) divided by kel</measure>
    <time_frame>One month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body temperature</measure>
    <time_frame>One month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12 Laed ECG, Lab Test ( Hematocrit, WBC count with differential, RBC count and platelet count ; SGOT ( AST), SGPT (ALT) , alkaline phosphatase, total bilirubin, albumin, glucose, BUN, creatinine,uric acid, total cholesterol and TG)</measure>
    <time_frame>One month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Brotizolam tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Brotizolam tablets 250mcg : at least 6 and 24 subjects will be enrolled in the pre-study and main study, respectively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lendormin tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lendormin tablets 250mcg: at least 6 and 24 subjects will be enrolled in the pre-study and main study, respectively</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lendormin tablet</intervention_name>
    <description>Lendormin tablet 250mc is administrated and compared</description>
    <arm_group_label>Lendormin tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brotizolam tablet</intervention_name>
    <description>Brotizolam tablet 250mc is administrated and compared</description>
    <arm_group_label>Brotizolam tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy volunteers, provision of signed written informed consent before enrolment into
             the study, ability to communicate with the investigators, and to understand and comply
             with the requirements of the study.

          2. Healthy adult male, aged between 20 and 40 years old.

          3. Body Mass Index (BMI) between 18.5 and 25, inclusive, (BMI will be calculated as
             weight in kilogram [kg]/height in meters2 [m2]).

          4. Physically and mentally healthy subjects as confirmed by an interview, medical
             history, clinical examination, chest x-ray and electrocardiogram.

          5. No significant deviation from normal biochemistry examination.

          6. No significant deviation from normal haematology examination.

          7. No significant deviation from normal urinalysis examination.

        Exclusion criteria:

          1. History of drug or alcohol abuse within the past one year.

          2. Medical history of allergic asthma or sensitivity to analogous drug.

          3. Evidence of chronic or acute infectious diseases from 4 weeks before the study.

          4. Evidence of any clinical significant renal, cardiovascular, hepatic, hematopoietic,
             neurological, pulmonary or gastrointestinal pathology.

          5. Ongoing peptic ulcer and constipation.

          6. Planned vaccination during the time course of the study.

          7. Taking any clinical investigation drug from 3 months before the study.

          8. Use of any medication, including herb medicine or vitamins from 4 weeks before the
             study.

          9. Donation of greater than 250 ml of blood in the past 3 months prior to dosing or
             donation of 250 ml of blood in the past 2 months prior to dosing.

         10. A positive Hepatitis B surface antigen or positive Hepatitis C antibody result.

         11. A positive test for HIV(Human immunodeficiency virus) antibody.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>263.511.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2011</study_first_submitted>
  <study_first_submitted_qc>May 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2011</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brotizolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

